Cargando…
The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients
Background. Immune activation has been implicated in the excess mortality in human immunodeficiency virus (HIV)-infected patients, due to cardiovascular diseases and malignancies. Statins may modulate this immune activation. We assessed the capacity of rosuvastatin to mitigate immune activation in t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731693/ https://www.ncbi.nlm.nih.gov/pubmed/26835476 http://dx.doi.org/10.1093/ofid/ofv201 |
_version_ | 1782412577357168640 |
---|---|
author | Weijma, Robyn G. M. Vos, Eric R. A. Ten Oever, Jaap Van Schilfgaarde, Muriel Dijksman, Lea M. Van Der Ven, André Van Den Berk, Guido E. L. Brinkman, Kees Frissen, Jos P. H. J. Leyte, Anja Schouten, Ineke W. E. M. Netea, Mihai G. Blok, Willem L. |
author_facet | Weijma, Robyn G. M. Vos, Eric R. A. Ten Oever, Jaap Van Schilfgaarde, Muriel Dijksman, Lea M. Van Der Ven, André Van Den Berk, Guido E. L. Brinkman, Kees Frissen, Jos P. H. J. Leyte, Anja Schouten, Ineke W. E. M. Netea, Mihai G. Blok, Willem L. |
author_sort | Weijma, Robyn G. M. |
collection | PubMed |
description | Background. Immune activation has been implicated in the excess mortality in human immunodeficiency virus (HIV)-infected patients, due to cardiovascular diseases and malignancies. Statins may modulate this immune activation. We assessed the capacity of rosuvastatin to mitigate immune activation in treatment-naive HIV-infected patients. Methods. In a randomized double-blind placebo-controlled crossover study, we explored the effects of 8 weeks of rosuvastatin 20 mg in treatment-naive male HIV-infected patients (n = 28) on immune activation markers: neopterin, soluble Toll-like receptor (TLR)2, sTLR4, interleukin (IL)-6, IL-1Ra, IL-18, d-dimer, highly sensitive C-reactive protein, and CD38 and/or human leukocyte antigen-DR expression on T cells. Baseline data were compared with healthy male controls (n = 10). Furthermore, the effects of rosuvastatin on HIV-1 RNA, CD4/CD8 T-cell count, and low-density lipoprotein cholesterol were examined and side effects were registered. Results. T-cell activation levels were higher in patients than in controls. Patients had higher levels of circulating IL-18, sTLR2, and neopterin (all P < .01). Twenty patients completed the study. Rosuvastatin increased the CD4/CD8 T-cell ratio (P = .02). No effect on other markers was found. Conclusions. Patients infected with HIV had higher levels of circulating neopterin, IL-18, sTLR2, and T-cell activation markers. Rosuvastatin had a small but significant positive effect on CD4/CD8 T-cell ratio, but no influence on other markers of T-cell activation and innate immunity was identified (The Netherlands National Trial Register [NTR] NTR 2349, http://www.trialregister.nl/trialreg/index.asp). |
format | Online Article Text |
id | pubmed-4731693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47316932016-01-31 The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients Weijma, Robyn G. M. Vos, Eric R. A. Ten Oever, Jaap Van Schilfgaarde, Muriel Dijksman, Lea M. Van Der Ven, André Van Den Berk, Guido E. L. Brinkman, Kees Frissen, Jos P. H. J. Leyte, Anja Schouten, Ineke W. E. M. Netea, Mihai G. Blok, Willem L. Open Forum Infect Dis Major Articles Background. Immune activation has been implicated in the excess mortality in human immunodeficiency virus (HIV)-infected patients, due to cardiovascular diseases and malignancies. Statins may modulate this immune activation. We assessed the capacity of rosuvastatin to mitigate immune activation in treatment-naive HIV-infected patients. Methods. In a randomized double-blind placebo-controlled crossover study, we explored the effects of 8 weeks of rosuvastatin 20 mg in treatment-naive male HIV-infected patients (n = 28) on immune activation markers: neopterin, soluble Toll-like receptor (TLR)2, sTLR4, interleukin (IL)-6, IL-1Ra, IL-18, d-dimer, highly sensitive C-reactive protein, and CD38 and/or human leukocyte antigen-DR expression on T cells. Baseline data were compared with healthy male controls (n = 10). Furthermore, the effects of rosuvastatin on HIV-1 RNA, CD4/CD8 T-cell count, and low-density lipoprotein cholesterol were examined and side effects were registered. Results. T-cell activation levels were higher in patients than in controls. Patients had higher levels of circulating IL-18, sTLR2, and neopterin (all P < .01). Twenty patients completed the study. Rosuvastatin increased the CD4/CD8 T-cell ratio (P = .02). No effect on other markers was found. Conclusions. Patients infected with HIV had higher levels of circulating neopterin, IL-18, sTLR2, and T-cell activation markers. Rosuvastatin had a small but significant positive effect on CD4/CD8 T-cell ratio, but no influence on other markers of T-cell activation and innate immunity was identified (The Netherlands National Trial Register [NTR] NTR 2349, http://www.trialregister.nl/trialreg/index.asp). Oxford University Press 2015-12-23 /pmc/articles/PMC4731693/ /pubmed/26835476 http://dx.doi.org/10.1093/ofid/ofv201 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
spellingShingle | Major Articles Weijma, Robyn G. M. Vos, Eric R. A. Ten Oever, Jaap Van Schilfgaarde, Muriel Dijksman, Lea M. Van Der Ven, André Van Den Berk, Guido E. L. Brinkman, Kees Frissen, Jos P. H. J. Leyte, Anja Schouten, Ineke W. E. M. Netea, Mihai G. Blok, Willem L. The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients |
title | The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients |
title_full | The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients |
title_fullStr | The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients |
title_full_unstemmed | The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients |
title_short | The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients |
title_sort | effect of rosuvastatin on markers of immune activation in treatment-naive human immunodeficiency virus-patients |
topic | Major Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731693/ https://www.ncbi.nlm.nih.gov/pubmed/26835476 http://dx.doi.org/10.1093/ofid/ofv201 |
work_keys_str_mv | AT weijmarobyngm theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vosericra theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT tenoeverjaap theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vanschilfgaardemuriel theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT dijksmanleam theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vandervenandre theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vandenberkguidoel theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT brinkmankees theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT frissenjosphj theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT leyteanja theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT schouteninekewem theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT neteamihaig theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT blokwilleml theeffectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT weijmarobyngm effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vosericra effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT tenoeverjaap effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vanschilfgaardemuriel effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT dijksmanleam effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vandervenandre effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT vandenberkguidoel effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT brinkmankees effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT frissenjosphj effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT leyteanja effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT schouteninekewem effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT neteamihaig effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients AT blokwilleml effectofrosuvastatinonmarkersofimmuneactivationintreatmentnaivehumanimmunodeficiencyviruspatients |